Abbot India reported 1.59% growth in total revenues for the Dec-20 quarter on consolidated basis at Rs1,095.37cr. Despite the pandemic, the top line revenues of the company have been largely stable each quarter over the last one year. It has seen continued traction in its pharmaceutical and health foods business.
The consolidated Profit after tax (PAT) for the Dec-20 quarter was down -5.12% at Rs177.14cr. While raw material costs were under control, the company did have to put up with larger purchases and also lower other income in the Dec-20 quarter. As a result, the PAT margins tapered from 17.31% in Dec-19 to 16.17% in Dec-20.
Financial highlights for Dec-20 compared yoy and sequentially
|
|
Abbott India |
|
|
|
|
|
Rs in Crore |
Dec-20 |
Dec-19 |
YOY |
Sep-20 |
QOQ |
|
Total Income (Rs cr) |
₹ 1,095.37 |
₹ 1,078.25 |
1.59% |
₹ 1,054.85 |
3.84% |
|
Net Profit (Rs cr) |
₹ 177.14 |
₹ 186.69 |
-5.12% |
₹ 180.73 |
-1.99% |
|
|
|
|
|
|
|
|
Diluted EPS (Rs) |
₹ 83.36 |
₹ 87.85 |
|
₹ 85.05 |
|
|
Net Margins |
16.17% |
17.31% |
|
17.13% |
|
Related Tags: